Abstract | BACKGROUND: METHODS: Patients with type 1, type 2, or mixed-type neovascularization (NV) were prospectively included. Participants underwent an initial loading phase of three consecutive monthly intravitreal injections of Conbercept (0.5 mg) and were switched to a pro re nata (PRN) treatment strategy. OCTA images were evaluated for eyes that underwent follow-up assessments for more than 6 months. CNV lesions were manually segmented, and the CNV area, vessel area, greatest vascular caliber (GVC), and greatest linear dimension (GLD) were compared between responders and non-responders. Two masked graders independently measured the above-mentioned parameters using OCTA, and consistency was assessed using the intraclass correlation coefficient (ICC) values. Multiple logistic regression analysis was performed to evaluate the effect of a 3-month change in the CNV area, GLD, and GVC on the 6-month response to anti- VEGF agents. RESULTS: Among the 60 eyes of 60 patients with nAMD, 39 were responders and 21 were non-responders. The proportion of CNV types was significantly different between responders and non-responders (P = 0.009). Patients with type 2 or mixed NV seemed more likely to respond to the treatment (28.2% vs. 0.0%, and 30.8% vs. 23.8%, respectively). The change in GVC showed a significant difference between responders (- 4.98 ± 17.17 μm) and non-responders (11.01 ± 14.10 μm) after three monthly intravitreal anti- VEGF injections. Multiple logistic regression analysis showed that only the change in GVC remained significant after controlling for baseline GVC, injection number, and CNV type (adjusted OR = 1.083; P = 0.008). CONCLUSIONS: Type 2 and mixed-type NV were significantly associated with a better response to anti- VEGF therapy. Changes in GVC after 3 months of treatment were significantly associated with a response to anti- VEGF therapy at 6 months.
|
Authors | Huixun Jia, Bing Lu, Zhi Zhao, Yang Yu, Fenghua Wang, Minwen Zhou, Xiaodong Sun |
Journal | Eye and vision (London, England)
(Eye Vis (Lond))
Vol. 9
Issue 1
Pg. 16
(May 01 2022)
ISSN: 2326-0254 [Print] England |
PMID | 35505390
(Publication Type: Journal Article)
|
Copyright | © 2022. The Author(s). |